Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Toripalimab Plus Actinomycin-D As Fist-Line Treatment in Patients with Gestational Trophoblastic Neoplasia with FIGO Score 7: a Single-Arm, Multicenter, Phase II Trial

NCT06020755 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT06020755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06020755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Toripalimab Plus Actinomycin-D As Fist-Line Treatment in Patients with Gestational Trophoblastic Neoplasia with FIGO Score 7: a Single-Arm, Multicenter, Phase II Trial
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
December 31, 2024
Completion date
August 31, 2025
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gestational trophoblastic neoplasia